ERBB2 and neoplasm: BC is routinely differentiated into diagnostic subtypes based on tumour biomarkers that influence treatment decisions, predominantly expression of human epidermal growth factor receptor 2 (HER2) and hormone receptors (HR; encompassing the oestrogen receptor and progesterone receptor).